Avivagen (VIVX.F) Stock Overview
Focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
VIVX.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Avivagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0072 |
| 52 Week Low | US$0.000001 |
| Beta | -13.75 |
| 1 Month Change | 0% |
| 3 Month Change | 9,900.00% |
| 1 Year Change | -83.33% |
| 3 Year Change | -99.95% |
| 5 Year Change | -99.98% |
| Change since IPO | -99.98% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| VIVX.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 10.3% | 1.2% |
| 1Y | -83.3% | -2.2% | 17.9% |
Return vs Industry: VIVX.F underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: VIVX.F underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| VIVX.F volatility | |
|---|---|
| VIVX.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VIVX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine VIVX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | G. F. Anthony | www.avivagen.com |
Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand.
Avivagen Inc. Fundamentals Summary
| VIVX.F fundamental statistics | |
|---|---|
| Market cap | US$7.77k |
| Earnings (TTM) | -US$3.22m |
| Revenue (TTM) | US$496.91k |
Is VIVX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIVX.F income statement (TTM) | |
|---|---|
| Revenue | CA$715.22k |
| Cost of Revenue | CA$409.83k |
| Gross Profit | CA$305.39k |
| Other Expenses | CA$4.95m |
| Earnings | -CA$4.64m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 42.70% |
| Net Profit Margin | -648.74% |
| Debt/Equity Ratio | -78.1% |
How did VIVX.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 16:02 |
| End of Day Share Price | 2024/10/02 00:00 |
| Earnings | 2023/07/31 |
| Annual Earnings | 2022/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avivagen Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Doug Cooper | Beacon Securities Limited |
| Joseph Gomes | NOBLE Capital Markets, Inc. |
| David Bautz | Zacks Small-Cap Research |